Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Toll Like Receptor 3 (CD283 or TLR3) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Stage of Development | 8 | 1 |
| Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Therapy Area | 9 | 1 |
| Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Indication | 10 | 2 |
| Toll Like Receptor 3 (CD283 or TLR3) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Companies | 14 | 3 |
| Toll Like Receptor 3 (CD283 or TLR3) Products under Development by Universities/Institutes | 17 | 2 |
| Toll Like Receptor 3 (CD283 or TLR3) Therapeutics Assessment | 19 | 7 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Toll Like Receptor 3 (CD283 or TLR3) Companies Involved in Therapeutics Development | 26 | 8 |
| Biomics Biotechnologies Co., Ltd. | 26 | 1 |
| Hemispherx Biopharma, Inc. | 27 | 1 |
| Idera Pharmaceuticals, Inc. | 28 | 1 |
| Innate Pharma S.A. | 29 | 1 |
| Johnson &Johnson | 30 | 1 |
| MultiCell Technologies, Inc. | 31 | 1 |
| Oncovir, Inc. | 32 | 1 |
| Tollys S.A.S | 33 | 1 |
| Toll Like Receptor 3 (CD283 or TLR3) Drug Profiles | 34 | 26 |
| Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases Drug Profile | 34 | 1 |
| Antisense RNAi Oligonucleotide to Agonize TLR-3 for Age Related Macular Degeneration Drug Profile | 35 | 1 |
| CNTO-3157 Drug Profile | 36 | 1 |
| Drugs to Activate TLR3 for Atherosclerosis Drug Profile | 37 | 1 |
| IPH-33 Drug Profile | 38 | 1 |
| MCT-465 Drug Profile | 39 | 2 |
| Oligonucleotide to Agonize TLR3 for Oncology Drug Profile | 41 | 1 |
| Oligonucleotides to Agonize TLR3 for Infectious Disease and Immunology Drug Profile | 42 | 1 |
| P-7 Drug Profile | 43 | 1 |
| Poly-ICLC Drug Profile | 44 | 3 |
| rabies vaccine Drug Profile | 47 | 1 |
| rintatolimod Drug Profile | 48 | 9 |
| Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome Drug Profile | 57 | 1 |
| Small Molecules to Antagonize TLR-3 for Infectious Disease and Immunology Drug Profile | 58 | 1 |
| Stathmin-1 Drug Profile | 59 | 1 |
| Toll Like Receptor 3 (CD283 or TLR3) Dormant Projects | 60 | 3 |
| Toll Like Receptor 3 (CD283 or TLR3) Discontinued Products | 63 | 1 |
| Toll Like Receptor 3 (CD283 or TLR3) Featured News &Press Releases | 64 | 13 |
| Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) in Expert Review of Clinical Pharmacology | 64 | 1 |
| Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property | 65 | 1 |
| Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke | 65 | 1 |
| Feb 09, 2016: Hemispherx Biopharma Exploring Possible Research Program in Zika Virus Using Ampligen | 66 | 1 |
| Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant | 66 | 2 |
| Sep 28, 2015: Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen Formulations | 68 | 1 |
| Sep 23, 2015: Hemispherx Biopharma Reports Article by Senior Authors from Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen to Multiple Sclerosis | 69 | 1 |
| Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen | 70 | 1 |
| Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study | 71 | 1 |
| Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms | 72 | 1 |
| Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe | 72 | 1 |
| Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations | 73 | 1 |
| May 26, 2015: Hemispherx Biopharma Europe : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease | 74 | 1 |
| May 11, 2015: Hemispherx Biopharma Europe Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD) | 74 | 1 |
| Mar 24, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD) | 75 | 2 |
| Appendix | 77 | 2 |
| Methodology | 77 | 1 |
| Coverage | 77 | 1 |
| Secondary Research | 77 | 1 |
| Primary Research | 77 | 1 |
| Expert Panel Validation | 77 | 1 |
| Contact Us | 77 | 1 |
| Disclaimer | 78 | 1 |